Chrome 2001
.
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
 
.
. .
.
Chrome 2001
Chrome 2001
Health News Health News
.
FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure Risk
February 11, 2014

 

TUESDAY, Feb. 11, 2014 (HealthDay News) -- The U.S. Food and Drug Administration announced Tuesday that it will investigate possible links between the diabetes drug saxagliptin and a heightened risk for heart failure among users.

In a statement, the agency said that the probe was spurred by "a study published [last September] in the New England Journal of Medicine, which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough."

Saxagliptin, which is marketed under the brand names Onglyza and Kombiglyze XR, is a relatively new diabetes medication that works by boosting the amount of insulin the body produces after each meal, when blood sugar levels are typically high.

The NEJM study did not find that saxagliptin had any effect on a patient's risk for heart attack or stroke.

However, "our data also show an increase in hospitalization for heart failure in patients who received saxagliptin, which was not expected and deserves further study," study chairman Dr. Eugene Braunwald, of Brigham and Women's Hospital and Harvard Medical School, said in a news release issued by the hospital when the study was published.

The research involved nearly 16,500 patients with type 2 diabetes from 26 countries. It was funded by drug makers AstraZeneca and Bristol Myers Squibb, which market saxagliptin.

The FDA said the information gleaned from the NEJM trial is considered "preliminary." The drug's makers now have until early March to submit detailed trial data to agency officials, "after which we will conduct a thorough analysis and report our findings publicly."

In the meantime, the agency said that "patients should not stop taking saxagliptin and should speak with their health care professionals about any questions or concerns."

The FDA said the probe into saxagliptin "is part of a broader evaluation of all type 2 diabetes drug therapies and cardiovascular risk."

Issues around the safety profiles of newer diabetes drugs gained prominence after the blockbuster medication Avandia was all but pulled from the market in 2010 due to heart safety concerns.

In a journal editorial accompanying the September NEJM study, experts noted that after Avandia gained FDA approval in 1999, one highly publicized review published in 2007 "reported a 43 percent increase in [heart attacks] and a 64 percent increase in death from cardiovascular causes" tied to use of the drug.

The editorial authors said the Avandia experience led the FDA to be highly cautious in its oversight of new diabetes medications. In 2008, the agency issued a new rule mandating that "pre-approval and post-approval studies for all new anti-diabetic drugs rule out excess cardiovascular risk."

Speaking at the time of the NEJM study's release, co-author Dr. Itamar Raz, head of the Prevention of Diabetes and Diabetes Clinical Research Center at Hadassah Medical Center in Israel, stressed that saxagliptin also showed benefits for patients.

"Patients who received saxagliptin also had better control of blood sugar levels and a reduced need for insulin therapy," he noted. Raz added that the diabetes drug also prevented the progression of microalbuminuria, a condition that occurs when a type of protein called albumin is spilling into the urine due to kidney damage.

Still, the final chapter on saxagliptin may have to wait until the FDA issues its findings on the detailed trial data.

Meanwhile, one expert said it's not easy for the millions of Americans with type 2 diabetes to know which drug is best for them.

Dr. Tara Narula, associate director of the cardiac care unit at Lenox Hill Hospital in New York City, said at the time of the study's publication that "there currently exists a tremendous amount of confusion regarding which diabetes drugs are safe to use in patients at risk for or with established cardiovascular disease."

More information

There's more on diabetes drugs at the American Diabetes Association.
Copyright © 2014 HealthDay. All rights reserved.


SOURCES: Itamar Raz, M.D., head, Prevention of Diabetes and Diabetes Clinical Research Center, Hadassah Medical Center, Israel; Tara Narula, M.D., associate director, cardiac care unit, Lenox Hill Hospital, New York City; Brigham and Women's Hospital, ne...

InteliHealth
.
.
.
.
.
More News
InteliHealth .
.
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
HIV/AIDS News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Schizophrenia
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
.
.
.
.
InteliHealth
    Print Printer-friendly format    
   
.  
This website is certified by Health On the Net Foundation. Click to verify.
.